- Pivot
offers unique proprietary drug delivery platform technologies
- Company
has a strong intellectual property (IP) portfolio for the formulation and
delivery of cannabinoids
- Company
acquires licensing rights to patented Trivair™ nasal and pulmonary drug
delivery system, also signs exclusive manufacturing agreement with Bio V
Pharma
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA:
NPAT) is a biopharmaceutical company based in Vancouver, British Columbia.
Pivot engages in the development and commercialization of premium
cannabinoid-based nutraceuticals and pharmaceuticals. It does so utilizing
unique drug delivery platform technologies. Pivot Pharmaceuticals’ wholly-owned
medical cannabis products division is Pivot Green Stream Health Solutions Inc.
(“PGS”).
Pivot Pharmaceuticals has a suite of 30 products ready for
commercialization. The company also has a strong intellectual property (IP)
portfolio for the formulation and delivery of cannabinoids. Pivot’s proposed
product line comprises capsules and tablets, bulk powder, stick packs and
beverages. Its product line also consists of water soluble oral solutions,
lotions, creams, gels and pet supplements.
Pivot Pharmaceuticals has acquired the global rights for
four proprietary drug delivery technologies. These technologies are for the
delivery and commercialization of cannabinoid-, cannabidiol- and
tetrahydrocannabinol-based products.
Researchers are continually working to design ways to breach
the blood brain barrier. However, as an article in life sciences magazine The
Scientist reported, “… researchers first have to understand it.” The
article notes that researchers are working on techniques to bypass or sneak
past the guardian of the central nervous system so they can better treat
neurological disease.
Pivot Pharmaceuticals recently signed an option agreement
with IP Med Inc. to acquire an exclusive global license for Trivair™ Nasal and
Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot’s
Ready-To-Infuse-Cannabis (RTIC) cannabinoid products (http://ibn.fm/Y1tSp). The
TriVair™ Nasal device uses the body’s natural breath to drive a medication deep
into the nasal cavity to targeted sites, bypassing the blood brain barrier and
providing the potential to better treat central nervous system diseases.
Pivot’s PGS division has acquired the worldwide rights to
the BiPhasix™ Transdermal Drug Delivery platform technology (topical).
BiPhasix™ is a dermal delivery technology for cannabinoids. Moreover, 1% CBD
BiPhasix Cream is ready for commercialization.
Additionally, PGS acquired the worldwide rights from Solmic
GmbH (Germany) for the development and commercialization of the Solmic
Solubilisation Technology Platform for defined cannabinoids or
cannabinoid-containing extracts. This formulation technology offers
considerably higher bioavailability and stability versus alternative oil-based
formulations.
Pivot’s other technology platform is Thrudermic™, a
transdermal nanotechnology for cannabinoids. Each of the company’s four
technology platforms allows Pivot to produce numerous products.
Pivot Pharmaceuticals also recently signed an exclusive
contract manufacturing agreement with Bio V Pharma Inc. (http://ibn.fm/MIxfo). This
agreement is for Bio V to manufacture, label, package and supply Pivot’s
bio-cannabis product pipeline. Bio V, based in the Province of Quebec, is a
full-service manufacturer of pharmaceutical and nutraceutical products. Bio V
will produce Pivot Pharmaceuticals’ complete bio-cannabis family of products.
This includes BiPhasix™ (topical creams and lotions), Thrudermic™ (transdermal
gels and lotions), Solmic™ 1% CBD oral solution, and Ready-to-Infuse-Cannabis
Powder.
In a news release, Dr. Patrick Frankham, chief executive
officer of Pivot Pharmaceuticals, stated, “We are excited to have chosen Bio V
Pharma as our Canadian manufacturing partner at this important time in Pivot’s
history. Consumers and regulators will demand high-quality products that are
manufactured in cGMP facilities by a knowledgeable and experienced team.”
For more information, visit the company’s website at www.PivotPharma.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
